See the full story in the original article.
Read the original on Yahoo Finance ↗
Related news
- Why Lucid Group Stock Is Moving in Reverse Today
Lucid Group (LCID) shares fell 9.4% as of 11:38 a.m. ET, extending last week's slide of more than 8%. RBC Capital kept its Sector Perform rating but cut its price target to $4 from $7, implying only 5.5% upside from Friday's close of $3.79. Lucid produced 2,954 vehicles and delivered 3,806 in the third quarter of 2026, versus 3,891 produced and 4,078 delivered in the same period of 2025. The company is in an “operating reset” targeting $1.4 billion in cash flow improvements in 2026, and the article says buying the stock is only suitable for investors with high risk tolerance until results appear.
- Stocktwits Zero To Sixty — Tesla’s Roadster Flies With SpaceX Thrusters, Rivian Opens Cars To AI Agents, And Lucid Eyes France
Tesla unveiled its redesigned Roadster near Waco, Texas, with SpaceX-derived thrusters that let it flip and hang upside down, and claimed 0 to 60 mph in under one second with a top speed above 230 mph. Production is slated for 2028 and the price is unannounced, though reservations list a $50,000 base model and a $250,000 Thrust variant. Rivian’s CEO said future vehicles will run AI agents from outside firms such as Anthropic, and the EPA approved 2027 commercial vans with a 129 kWh battery. Lucid plans to start French deliveries in the first quarter of 2027 with partner Emil Frey France. China approved a Ford–Geely joint venture to build a Blue Oval SUV at Ford’s Valencia plant in Spain, targeted for 2028, while GM CEO Mary Barra reaffirmed eyes-off driving by 2028 starting with the Cadillac Escalade IQ and defended the exit from Cruise after spending more than $10 billion.
- Tesla Rises 4% on Thruster-Powered Roadster Reveal; Rivian Edges Higher, Lucid Holds Steady
Tesla shares rose 4% to $375.29 in morning trading after the company unveiled a redesigned Roadster using thruster hardware borrowed from SpaceX. At a Texas rocket test site, the car flipped midair and landed during the demonstration. Pricing and a road-approval path have not been announced. Tesla shares are still down 17% year to date, while Rivian (up 1% to $13.15) and Lucid (flat at $3.50) are down 33% and 67% YTD respectively. Tesla's Q2 revenue rose 25.5% to $28.24 billion, but adjusted EPS of $0.33 missed the $0.54 estimate.
- Tesla Faces New Luxury EV Rival in France as Lucid Plans 16 Locations
Lucid Group plans to open its first three retail and service locations in France in the first quarter of 2027, with more than 16 partner locations targeted by the end of that year, working with Emil Frey France. Customers will be able to experience and order the Air sedan and Gravity SUV, with priority reservations already open on Lucid's French website and orders expected to open in the first quarter of 2027. France is an attractive market, as electric vehicles made up 42% of new car registrations in September according to Reuters, but Tesla already has a broad network of stores and service centers there. Lucid's current challenge is more immediate: it delivered 3,806 vehicles in the third quarter of 2026, below the 4,687 average analyst estimate, and production fell to 2,954 as it cut costs. The bigger test is turning its products and new retail presence into sustained sales.
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's Foundayo, an oral GLP-1 weight-loss medicine approved in the U.S. in April, is drawing new patients, with 80% of its prescriptions earlier this year going to people who had never taken a GLP-1 medicine before. The company's Onswik, a once-weekly basal insulin for diabetes approved in September, could strengthen its diabetes portfolio, though Novo Nordisk's Awiqli was approved first in March. The investigational retatrutide showed average weight loss of up to 28.3% over 80 weeks in one Phase 3 study, and Eli Lilly plans to submit it for regulatory approval in the first quarter of 2027. The article argues these drugs could power Eli Lilly's next phase of growth beyond Zepbound.
- Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Vertex Pharmaceuticals closed its roughly $10 billion cash acquisition of Crinetics Pharmaceuticals in September, its largest deal to date. Crinetics' approved product Palsonify, launched in the U.S. last year, is indicated as a first-line treatment for acromegaly in patients who are not eligible for surgery or for whom surgery did not work, and is taken as a once-daily oral pill. Vertex estimates 20,000 patients diagnosed with acromegaly in the U.S. and 35,000 outside the U.S., while only 40% to 50% achieve durable remission after surgery. The deal also brought atumelnant, which is in Phase 3 studies for congenital adrenal hyperplasia and Phase 2 trials for Cushing's syndrome. Vertex estimates Palsonify and atumelnant could eventually generate peak revenue above $5 billion, compared with $12 billion in company revenue last year, while sales growth in its core cystic fibrosis franchise has slowed.
Related markets
Latest news
- Bitcoin ETFs just saw their biggest day in a month thanks entirely to BlackRock
U.S. spot bitcoin ETFs took in $526.6 million on Monday, the largest daily net inflow in nearly a month, driven entirely by BlackRock's iShares Bitcoin Trust (IBIT), which pulled in $665.2 million, its biggest daily inflow since Oct. 7 last year, according to SoSoValue data. Fidelity's FBTC lost $83.6 million and Grayscale's GBTC shed $54.9 million, while the remaining funds recorded no net flows. The inflow more than erased last week's $228.5 million of withdrawals, but funds remain about $90.5 million in net outflows for October, according to CoinDesk calculations. Ether funds moved the opposite way, losing $103.3 million in their fourth consecutive session of outflows, with BlackRock's ETHA accounting for $95.4 million of that.
- A Big4 bank cut deposit rates in the morning, then raised them again in the afternoon
VietinBank cut its deposit rates for terms of 6 months and longer on the morning of Oct. 20, then restored them to pre-adjustment levels by the afternoon. Its afternoon rate board showed 3.5% per year for 6 to under 12 months, 5.9% for 12 to under 24 months and 6% for 24 months and longer, versus 3%, 5.4% and 5.5% in the morning. Rates for terms under 6 months stayed unchanged, including 2.1% for 1 to under 3 months and 2.4% for 3 to under 6 months. The move came as banks followed the State Bank of Vietnam's guidance to cut deposit rates by at least 0.5 percentage points for terms of 6 months and longer, and Vietcombank and Agribank were among those reducing rates.
- IVV vs. SPY: Which S&P 500 ETF Is the Better Buy for Long-Term Investors?
The article compares two ETFs that track the S&P 500, iShares Core S&P 500 ETF (IVV) and State Street SPDR S&P 500 ETF (SPY), which have nearly identical holdings. The main difference is the expense ratio: IVV charges 0.03% a year, one-third of SPY's 0.09%, and its distribution yield is about 1.1% versus 1% for SPY. SPY's high liquidity remains valuable for active traders. The article concludes that IVV is the better choice for long-term investors, since lower costs can compound over time.
- Warren Buffett Is Issuing a Stark Warning About the Stock Market. Here's What History Says Comes Next.
Warren Buffett has warned that investors are taking on too much risk, likening the market to 'a church with a casino attached' and saying people have never been in a more gambling mood. The article points to the S&P 500 Shiller CAPE Ratio, which has stayed above 40 since May of this year; historically, the only other time it held above that level for months was during the dot-com bubble, when it peaked around 44 before the bear market began in March 2000. The article notes that 40 is not an automatic trigger for a downturn, and no metric can predict timing. It suggests investors focus on quality stocks with solid fundamentals and be ready to hold them for at least a few years.
- Early Uber Investor Jason Calacanis Predicts Waymo Could Buy Lucid Or Rivian — Calls Its Chinese-Car Optics ‘Really Bad’
Early Uber investor Jason Calacanis predicts Waymo will buy Lucid Group (LCID) or Rivian Automotive (RIVN), arguing that its reliance on Chinese-made Zeekr vehicles creates cost and reputational problems. He says the arrangement is technically not illegal today, but Waymo would need to pay a tariff of over 100%, and it has drawn national-security concerns on Capitol Hill. According to Semafor, Waymo aims to grow its fleet from about 4,000 vehicles to 8,000 by the end of 2026 and 20,000 by the end of 2027, after closing a $5 billion term loan and a $16 billion equity raise this year. Uber has committed to buying at least 35,000 Lucid vehicles, while its Rivian deal starts with 10,000 autonomous R2 SUVs, with rides expected to begin in 2028. Calacanis, who recently bought small stakes in Lucid, Rivian, WeRide (WRD) and Pony.ai (PONY), expects consolidation in the autonomous-driving sector within 24 months.
- Prediction: Oct. 21 Will Be a Huge Day for the Stock Market
The article predicts October 21 could be a pivotal day for the stock market, as Meta Platforms (META) becomes the first of the "Magnificent Seven" tech giants to report third-quarter earnings after the close. In its latest quarter, Meta's total revenue rose 28% to $60 billion, with ad revenue at $59 billion. Investors will be watching whether its capital spending, now about 35% of revenue, is translating into growth. Meta's report could hint at the earnings outlook for other tech giants and set the direction for the S&P 500 in the coming days, with the first trading session after the report on Thursday.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.